Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome
0
Authors
Sidney Lerman
Sidney Lerman•Maria Fleseriu•Roy Weiss
Published
April 1, 2012
Abstract
Context:Cushing's syndrome (CS) is a disorder associated with significant morbidity and mortality due to prolonged exposure to high cortisol concentrations.
